Lupin falls; Mylan launches cholesterol drug
Reuters Market Eye - Shares in Lupin Ltd (LUPN.NS) slump 4 percent after earlier falling as much as 4.7 percent following the launch of rival Mylan Inc's (MYL.O) generic version of the cholesterol-lowering Tricor tablets.
Mylan Inc said in a statement on Friday its unit Mylan Pharmaceuticals Inc has shipped generic Tricor, or fenofibrate tablets, of 48 mg and 145 mg.
Mylan compete against Lupin, which also sells generic versions of Tricor.
"Mylan's launch of Tricor will result in higher competition and decline in Lupin's market share in a drug which has a market size of $1.2 billion," said Ranjit Kapadia, senior vice president at Centrum Broking.
(Reporting by Abhishek Vishnoi)
- Tweet this
- Share this
- Digg this
- U.S. Treasury moves against tax-avoidance 'inversion' deals
- Chinese and Indian troops in Himalayan standoff
- India withdraws regulator's power to cap non-essential drug prices
- India's Mars mission a step closer to success with engine test
- U.S. and Arab allies launch first strikes on fighters in Syria
India has withdrawn the drug pricing authority's powers that allowed it to fix the prices of medicines not deemed essential, after its decision to impose price caps on more than 100 drugs in July triggered industry protests. Article